Favipiravir: A new and emerging antiviral option in COVID-19

Furuta, 2013, Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antivir Res, 100, 446, 10.1016/j.antiviral.2013.09.015

Toyama Chemicals. Summary of Product Characteristics of Avigan.

Madelain, 2016, Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials, Clin Pharmacokinet, 55, 907, 10.1007/s40262-015-0364-1

Jin, 2013, The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase, PloS One, 8, 10.1371/journal.pone.0068347

Baranovich, 2013, 705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro, J Virol, 87, 3741, 10.1128/JVI.02346-12

Sleeman, 2010, In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses, Antimicrob Agents Chemother, 54, 2517, 10.1128/AAC.01739-09

Oestereich, 2014, Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antivir Res, 105, 17, 10.1016/j.antiviral.2014.02.014

Smither, 2014, Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model, Antivir Res, 104, 153, 10.1016/j.antiviral.2014.01.012

Sissoko, 2016, Experimental treatment with favipiravir for ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea, PLoS Med, 13

Kerber, 2019, Laboratory findings, compassionate use of favipiravir, and outcome in patients with ebola virus disease, Guinea, 2015-A retrospective observational study, J Infect Dis, 220, 195, 10.1093/infdis/jiz078

Shannon, 2020

Furuta, 2002, In vitro and in vivo activities of anti-influenza virus compound T-705, Antimicrob Agents Chemother, 46, 977, 10.1128/AAC.46.4.977-981.2002

Nguyen, 2017, Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted, PLoS Neglected Trop Dis, 11, 10.1371/journal.pntd.0005389

Wang, 2020, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, 30, 269, 10.1038/s41422-020-0282-0

Chen, 2020

Cai, 2020

James Ives

Doi, 2020, Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series, Crit Care, 24, 392, 10.1186/s13054-020-03078-z

Personal Communication..

Pharmaceuticals and Medical Devices Agency, 2011

Kumagai, 2015, Lack of effect of favipiravir, a novel antiviral agent, on the QT interval in healthy Japanese adults, Int J Clin Pharm Ther, 53, 10.5414/CP202388

Pilkington, 2020, A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?, J Virus Erad, 6, 45, 10.1016/S2055-6640(20)30016-9

Catherine, 2020

Beigel, 2020, Remdesivir for the treatment of covid-19 - preliminary report, N Engl J Med, 10.1056/NEJMoa2007764

Grein, 2020, Compassionate use of remdesivir for patients with severe covid-19, N Engl J Med, 382, 2327, 10.1056/NEJMoa2007016

Heneghan, 2016, Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data, Health Technol Assess, 20, 1, 10.3310/hta20420

2020

Tirumalaraju, 2020